Pfizer, Lilly’s NGF painkiller meets endpoints in low back pain by Conor Hale Tuesday, February 19, 2019 Eli Lilly and Pfizer’s nonopioid NGF inhibitor tanezumab beat out placebo in a phase 3 study of patients with chronic lower back pain.
Solid Bio plummets on early DMD gene therapy readout by Phil Taylor Thursday, February 7, 2019 Solid Bio’s run of negative news is continuing with another setback for its Duchenne muscular dystrophy gene therapy.
UPDATED: Amid R&D rejigs, GlaxoSmithKline axes 6 pipeline assets by Ben Adams Wednesday, February 6, 2019 GlaxoSmithKline is cutting a host of unwanted investigational drugs as it joins other Big Pharmas in the fourth-quarter clearout.
Pfizer/Lilly NGF pain drug wins again, but safety issue lingers by Phil Taylor Tuesday, January 29, 2019 Pfizer and Lilly now have two trials showing NGF blocker tanezumab reduces pain in arthritis, but cases of rapid joint damage are still seen.
Pfizer inks deal to use CytoReason's cell-centered models by Joseph Keenan Thursday, January 17, 2019 Pfizer has inked a deal with CytoReason to use its cell-centered models of the immune system for drug discovery.
Cellectis CEO Choulika on the future of CAR-T by Amirah Al Idrus Tuesday, January 8, 2019 Allogeneic CAR-T therapy, which uses donor T cells, has the potential to clear the hurdles that come with autologous CAR-T, which uses a patient’s own T cells.